Ciluprevir
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 300832-84-2 |
PubChem (CID) | 9853710 |
ChemSpider | 8029420 |
UNII | 75C8DU40T0 |
ChEMBL | CHEMBL297884 |
Chemical and physical data | |
Formula | C40H50N6O8S |
Molar mass | 774.93 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the research code of BILN-2061. It is targeted against NS2-3 protease.[1]
References
- ↑ Abbenante, G; Fairlie, DP (2005). "Protease inhibitors in the clinic". Medicinal chemistry. 1 (1): 71–104. doi:10.2174/1573406053402569. PMID 16789888.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.